Through many years of involvement and achievements in the pharmaceutical industry, Skyepharma’s development and manufacturing facility is a leader in the field of classic and complex oral solid dosage forms.
More than 20 years of experience in complex oral forms
Jacques Gonnella creates JAGO AG, a small Swiss private company specialized in development.
Ian Gowrie-Smith, founder of Medeva, creates SkyePharma plc as a virtual entity. Skyepharma then acquires JAGO AG, operating under that name before rebranding as Skyepharma AG two years later.
Skyepharma acquires its Saint-Quentin-Fallavier production site from Wyeth*. Skyepharma has subsequently invested in the site to adapt it to the production of modified-release tablets, particularly those using the patented Geomatrix® technology.
Skyepharma develops its business by acquiring several companies:
- The American company Depotech (San Diego), specialized in the development of sustained-release injectables, which became “Skyepharma Inc”.
- Bioglan Pharma (DK) and Hyal Pharmaceutical (Canada) Corporation, both specialized in topical products. Hyal originated Solaraze.
- The Montreal-based RTP pharma company that was the origin of Triglide.
* The Saint-Quentin-Fallavier plant was built in 1990 by the American laboratory Lederle, then a subsidiary of the American Cyanamid chemical group (Lederle then became Wyeth-Lederle, a subsidiary of the American Home Products group, which was itself acquired by Pfizer). The site replaced the former Oullins (Rhône) plant.